A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provide... (mportant therapeutic targets independent...)

A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits

Date:7/14/2009

mportant therapeutic targets independent of beta amyloid," Gandy added.

The researchers note that so far they only studied acute systems, and it is conceivable that the chronic effect of dimebolin could be amyloid-lowering.

Immunotherapy Against Tau Tangles in Alzheimer's Mouse Models

Immunotherapy (treatment by inducing, enhancing, or suppressing an immune response) targeting beta amyloid is being researched widely by companies and academics as a therapeutic option for Alzheimer's disease. Earlier, late stage, anti-amyloid immunotherapy trials in people were complicated, and eventually stopped, when about six percent of participants developed brain inflammation. Current trials in this area are working in a variety of ways to eliminate this side effect.

Tau tangles, the other major Alzheimer's brain pathology, are now also receiving attention as a target for immunotherapy. Also known as neurofibrillary tangles (NFTs), these lesions consist of an abnormal folded protein (phosphorylated tau), and research shows their accumulation in the brain is more closely associated with the progression of Alzheimer's symptoms than amyloid.

Building on previous studies using this approach (for example, Asuni et al. (2007)), Hanna Rosenmann, Ph.D., head of the Laboratory of Molecular Neurogenetics, Department of Neurology, Hadassah University Hospital, Ein Kerem, and an Investigator (Associate-Senior Lecturer) at the Hebrew University Hadassah School of Medicine, Jerusalem, Israel, and colleagues performed immunization studies against tau tangle pathology by immunizing NFT mice with a mixture of three phosphorylated-tau peptides (shortened versions of the full length tau protein that are phosphorylated like the NFTs). Previous experiments by this lab with non-phosphorylated full length tau caused brain inflammation in the animal models.

The researchers ob
'/>"/>

SOURCE Alzheimer's Association
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug

Post Your Comments:

(Date:12/15/2009)... -- "The entire San Diego Hospice and The Institute ... Price on December 14, 2009. Mr. Price has been ... ethics in his business, community and personal life. Mr. ... understood the responsibility of philanthropy and the role it ... on through his countless philanthropic efforts. We extend our ...

(Date:12/14/2009)... Unmarried Young Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, ... Nearly all unmarried young adults ages 18-29 ... of men and 86% of women) and say that ... right now (86% of men and 88% of women), ... to Prevent Teen and Unplanned Pregnancy. Even so: ...

(Date:12/14/2009)... -- Pepsi Bottling Group, ArvinMeritor, Inc., Marathon Oil ... the major employers that implemented Thomson Reuters Informed ... make better decisions about their benefits. ,, The ... of their families, use of healthcare services and ... information, employees can determine which of the available ...

(Date:12/14/2009)... 14 Haemonetics Corporation (NYSE: ... a new legal action to stop Fenwal Inc.,s ... red cell collection kits, using a modified separation ... to circumvent Haemonetics, patent and the injunction entered ... infringing products after December 1, 2010. According ...

(Date:12/14/2009)... Dec. 14 Tough Enough To Wear Pink(TM) ... cancer, celebrated its fifth anniversary at the signature ... Wrangler National Finals Rodeo (Wrangler NFR) in Las ... rough-and-tumble rodeo cowboys, the support of the western ... sold-out crowd sported pink shirts, hats, bracelets and ...

Breaking Medicine News(10 mins):Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3 Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4

[1] San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price [1] Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference [0] Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process [0] Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement [0] Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary

... The Westaim Corporation,announced today that for the first quarter ended ... or 7 cents per share, on revenues of,$5.2 million. In ... of $6.7 million, or 7 cents per share, on revenues ... million for the quarter,compared to $1.9 million in the same ...

... the University of Michigan Comprehensive Cancer Center have found ... more likely to survive cancers of the base of ... found that cancers linked to HPV, or human papillomavirus, ... treatments, while tumors that express high levels of a ...

... Graduate Institute (KGI),today announced that the May 17, 2008, ... in Applied Life Sciences student, Eric,Tan, and the unveiling ... excited and proud of Eric,s achievement in becoming the,first ... Dewey, KGI,s senior,vice president for academic affairs, dean of ...

... VANCOUVER, May 12 /PRNewswire-FirstCall/ - Cardiome Pharma Corp.,(NASDAQ: CRME ... financial,results for the first quarter of 2008 on the ... teleconference call and webcast at 4:30pm,Eastern (1:30pm Pacific) on ... the conference call, please dial 416-641-6117 or,866-299-6655. There will ...

... Slides at 5pm Today, LAWRENCE, Mass., May 12 ... manufacturer of innovative dialysis products,today announced its financial results ... for the first quarter of 2008 were $31.0 million, ... and $29.9 million in the fourth,quarter of 2007. Revenues ...

... - SXC Health Solutions, Corp.,(NASDAQ: SXCI , TSX: ... healthcare IT solutions, announced today that its,2007 Annual Meeting ... 2008 at,5:30 p.m. Eastern Time/4:30 p.m. Central Time at ... The presentation will be webcast live. To access the ...

Westaim announces 2008 first quarter results HPV linked to better survival in tonsil, tongue cancer, U-M study finds KGI 2008 Commencement Features First PhD Graduate, Biotech Painting Cardiome To Release 2008 First Quarter Results NxStage Medical Reports First Quarter 2008 Results SXC Health Solutions to host annual meeting of shareholders May 12, 2008 at 5:30 pm ET/4:30 pm CT

(Date:12/14/2009)... THE WOODLANDS, Texas, Dec. 14 /PRNewswire/ ... investigators affiliated with US Oncology ... were presented orally at the ... , held Dec. 9-13 at the ... in San Antonio, Texas . ...

(Date:12/14/2009)... Health today announced that executives of the company will ... Goldman Sachs CEO Unplugged Conference on Jan. 6 ... in New York. 28th Annual J.P. Morgan ... at the Westin St. Francis Hotel in San Francisco. ... Cardinal Health,s diverse products and services, company performance and ...

(Date:12/14/2009)... Dec. 14 Southridge LLC ("Southridge"), ... micro-cap companies, is pleased to announce that its affiliated ... up to $15 million in equity financing to Imaging ... the years of financing the growth of Imaging Diagnostic ... continually produce new developments in the field of early ...

Breaking Medicine Technology:US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9 Cardinal Health Executives to Speak at Two Investor Events in January 2 Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2 Spike Footballs this Fall Without Straining the Spine 54231 1 Spike Footballs this Fall Without Straining the Spine 54231 2 Leading Medical Developer Announces Plans for Texoma Medical Plaza 54227 1 Leading Medical Developer Announces Plans for Texoma Medical Plaza 54227 2 Leading Medical Developer Announces Plans for Texoma Medical Plaza 54227 3 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 4846 1 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 4846 2 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 4846 3

[0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium [0] Cardinal Health Executives to Speak at Two Investor Events in January [0] Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc.

... SAN DIEGO, Jan. 22 Meritage Pharma, Inc. announced ... clinical trial to evaluate oral viscous budesonide (OVB) for ... (EoE), an allergic inflammatory condition of the esophagus. EoE ... severe cases it can lead to food impaction (food ...

... January 21 PharmaSurgics AB has,received approval from ... phase,I clinical documentation with the novel candidate drug, ... will be initiated in,March 2009. , ... that connect anatomic structures that,should not normally be ...

Other Medicine Technology:Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis 2 Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis 3 Novel Product for Post Surgical Scar Formation Entering Clinical Development 2

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis Novel Product for Post Surgical Scar Formation Entering Clinical Development

... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...

... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...

... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...

... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...

Medicine Products:

BEN/1Q-CAB-ERB - Reinforced Nylon Base - Model 1Q43-CAB-ERB BEC/1Q-ERB - Cast Aluminum Base - Model 1Q66-R-ERB BEN/1Q-CAB-ERB - Reinforced Nylon Base - Model 1Q70-CAB-ERB BEC/1Q-ERB - Cast Aluminum Base - Model 1Q73-ERB

A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provide...(mportant therapeutic targets independent...),Health